Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.
The webcast will include a presentation and Q&A session with
The
In late summer Sangamo plans to present preliminary data from the Phase 1/2 clinical trial evaluating SB-913 for MPS II ("the CHAMPIONS study").
About
Forward-Looking Statements
This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, references to Sangamo's plan to present preliminary clinical data from the CHAMPIONS study in late summer.
These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the dependence on the success of clinical trials of lead programs, the lengthy and uncertain regulatory approval process, uncertainties related to the initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of Sangamo's therapeutics, and the reliance on partners and other third-parties to meet their obligations. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable gene-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the
View original content with multimedia:http://www.prnewswire.com/news-releases/sangamo-to-host-educational-webcast-with-hunter-syndrome-mps-ii-expert-joseph-muenzer-md-phd-300687645.html
SOURCE
Sangamo Therapeutics, Inc., McDavid Stilwell, 510-970-6000, x219, mstilwell@sangamo.com; or Varant Shirvanian, 510-970-6000 x205, vshirvanian@sangamo.com